Compare FSV & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | ROIV |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 25.1B |
| IPO Year | 2015 | 2021 |
| Metric | FSV | ROIV |
|---|---|---|
| Price | $132.52 | $40.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $208.25 | $28.94 |
| AVG Volume (30 Days) | 176.7K | ★ 7.9M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.79 | $744.61 |
| P/E Ratio | $49.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $119.41 | $13.94 |
| 52 Week High | $205.69 | $42.50 |
| Indicator | FSV | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 60.38 |
| Support Level | $122.19 | $33.15 |
| Resistance Level | $146.14 | $42.50 |
| Average True Range (ATR) | 3.41 | 1.51 |
| MACD | -0.95 | 0.42 |
| Stochastic Oscillator | 10.37 | 67.36 |
FirstService Corp is engaged in outsourcing property services. The company operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertaPro Painters, Floor Coverings International, and Pillar to Post Home Inspectors. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.